CoChat

Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety

Open access
Bailey, Jayne E, Papadopoulos, Andreas, Diaper, Alison, Phillips, Suzanne, Schmidt, ME, van der Ark, P, Dourish, Colin T, Dawson, Gerard R, Nutt, David J · 2011 · Journal of Psychopharmacology
Cited by 55

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

We have validated the use of prolonged inhalation of 7.5% carbon dioxide (CO 2) as a human model of anxiety and have shown that drugs from two prototypical classes of anxiolytics, benzodiazepines and a serotonin reuptake inhibitor, attenuate CO 2-induced symptoms ( Bailey et al., 2007a ). Preclinical evidence suggests that drugs acting at the corticotropin-releasing factor (CRF) system may be useful for the treatment of depression, anxiety, and other stress-related disorders ( Valdez, 2006 ), hence we have now examined the effects of a CRF 1 receptor antagonist in the 7.5% CO 2 model. In a randomized double-blind, placebo-controlled, study in 32 healthy participants we examined the effects of 7 days of treatment with the CRF 1 receptor antagonist, R317573, at a dose that shows a favourable safety profile and is comparable with those effective in preclinical models (40 mg). On day 8, eight of the placebo-treated group received lorazepam (LZP) 2 mg as a positive control. All participants underwent 20 min inhalation of 7.5% CO 2-enriched air. Subjective reports of peak gas effects were assessed using visual analogue scales and questionnaires. The mean age of participants was 26 years, and 13 were male. The peak effects of CO 2 were expressed as a difference from baseline scores obtained while breathing air alone. Compared with placebo (PLAC), both drug groups showed a decrease in all subjective symptoms, total score on the panic symptom inventory (CRF 11 [2.6], PLAC 16.4 [3.1], LZP 2.9 [3.0]) and a generalized anxiety disorder symptom scale (CRF 2.2 [1.5], PLAC 8.2 [2.2], LZP 1.1 [1.5]). We have shown that a drug that acts to inhibit the CRF 1 receptor shows efficacy in the 7.5% CO 2 model of anxiety in healthy participants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881111400650

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 55

Metadata

Authors
Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., Dourish, C. T., Dawson, G. R., & Nutt, D. J.
Venue
Journal of Psychopharmacology
Published
2011-05-09
Volume
25
Issue
9
Pages
1199-1206
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2033909710
Cited by
55
References
1
FWCI
2.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. https://app.cochat.ai/papers/10.1177/0269881111400650
The paper
Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., Dourish, C. T., Dawson, G. R., & Nutt, D. J. (2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology. https://doi.org/10.1177/0269881111400650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.